Literature DB >> 33911766

A Case of Capecitabine-Induced Discoid Lupus Erythematosus.

Ji Hye Heo1, Han Na Hyun2, Seon Bok Lee1, Hee Seong Yoon1, Si Hyub Lee1, Seung Dohn Yeom1, Jeonghyun Shin1, Gwang Seong Choi1, Ji Won Byun1.   

Abstract

Entities:  

Year:  2020        PMID： 33911766      PMCID： PMC7992649          DOI： 10.5021/ad.2020.32.4.348

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN： 1013-9087            Impact factor:   1.444


× No keyword cloud information.
  5 in total

Review 1.  A systematic review of drug-induced subacute cutaneous lupus erythematosus.

Authors:  G C Lowe; G Lowe; C L Henderson; R H Grau; C B Hansen; R D Sontheimer
Journal:  Br J Dermatol       Date:  2011-02-17       Impact factor: 9.302

2.  Discoid lupus erythematosus (DLE)-like lesions induced by capecitabine.

Authors:  F Merlin; T Prochilo; B Kildani; C Lombardi; G Pasolini; F Bonetti; G D Beretta
Journal:  Int J Colorectal Dis       Date:  2008-03-11       Impact factor: 2.571

3.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.

Authors:  J Schüller; J Cassidy; E Dumont; B Roos; S Durston; L Banken; M Utoh; K Mori; E Weidekamm; B Reigner
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

Review 4.  The evolution of fluoropyrimidine therapy: from intravenous to oral.

Authors:  P M Hoff; J Cassidy; H J Schmoll
Journal:  Oncologist       Date:  2001

5.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Authors:  M Miwa; M Ura; M Nishida; N Sawada; T Ishikawa; K Mori; N Shimma; I Umeda; H Ishitsuka
Journal:  Eur J Cancer       Date:  1998-07       Impact factor: 9.162
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.